http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2596792-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d57280bacbf75fa6d42418b6ec8ab92d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2015-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_108eeae8d76cc6b2229e21c7b7a47be8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd01c1d02d15c1e697f852c57b803543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9048b3bbd17921e450c20311b5753dde http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_425f19d6610da8d6882be30be2774f15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82a314a70a1e75fa8e17a525a0b09314 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90dfc93794f626cd1be323880a649939 |
| publicationDate | 2016-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2596792-C1 |
| titleOfInvention | Method of treating multiple sclerosis in children |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, particularly to neurology, and can be used in medical practice for treating multiple sclerosis (MS) in children. Method involves plasmapheresis, immunocorrecting and antiviral therapy. Herewith 2 times a year with the gap of 6 months 1 session is performed of cascade plasma exchange of one volume of circulating plasma, then intravenously immunoglobulin G is introduced by drop infusion in the dose of 0.2-0.4 g/kg for 2 days. Then intravenously Ronkoleukin is introduced by drop infusion in the dose of 0.5 mg/day for two days followed by prescribing Viferon in the dose of 3 million IU a day 3 times a week for 1 month in relapsing remitting multiple sclerosis and for 3 months in secondary (or primary) progressive multiple sclerosis. n EFFECT: invention usage allows to reduce the frequency of MS exacerbations, reduce indices of disability, reduce the term of treatment. n 1 cl, 4 tbl, 3 ex |
| priorityDate | 2015-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.